BG110467A - Treatment of neurotic disorders - Google Patents

Treatment of neurotic disorders Download PDF

Info

Publication number: BG110467A
Authority: BG; Bulgaria
Prior art keywords: test; treatment; disorder; day; disorders
Prior art date: 1999-07-08

Application number

BG11046709A

Other languages

Bulgarian (bg)

English (en)

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-07-08

Filing date

2002-01-04

Publication date

2010-01-29

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8099796&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BG110467(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2002-01-04 Application filed filed Critical

2010-01-29 Publication of BG110467A publication Critical patent/BG110467A/bg

Links

238000011282 treatment Methods 0.000 title claims abstract description 16
208000015238 neurotic disease Diseases 0.000 title abstract description 10
206010029333 Neurosis Diseases 0.000 title abstract description 9
150000003839 salts Chemical class 0.000 claims abstract description 10
206010041250 Social phobia Diseases 0.000 claims abstract description 7
238000002360 preparation method Methods 0.000 claims abstract description 7
WSEQXVZVJXJVFP-FQEVSTJZSA-N escitalopram Chemical compound C1([C@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 WSEQXVZVJXJVFP-FQEVSTJZSA-N 0.000 claims description 15
229960004341 escitalopram Drugs 0.000 claims description 14
239000003814 drug Substances 0.000 claims description 10
239000004480 active ingredient Substances 0.000 claims description 7
208000019906 panic disease Diseases 0.000 abstract description 19
206010033664 Panic attack Diseases 0.000 abstract description 13
229960001653 citalopram Drugs 0.000 abstract description 9
WSEQXVZVJXJVFP-HXUWFJFHSA-N (R)-citalopram Chemical compound C1([C@@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 WSEQXVZVJXJVFP-HXUWFJFHSA-N 0.000 abstract description 8
208000021384 Obsessive-Compulsive disease Diseases 0.000 abstract description 8
208000011688 Generalised anxiety disease Diseases 0.000 abstract description 5
208000029364 generalized anxiety disease Diseases 0.000 abstract description 5
208000019901 Anxiety disease Diseases 0.000 abstract description 4
208000028173 post-traumatic stress disease Diseases 0.000 abstract description 4
230000036506 anxiety Effects 0.000 abstract description 2
238000012360 testing method Methods 0.000 description 32
230000000694 effects Effects 0.000 description 19
241000700159 Rattus Species 0.000 description 15
150000001875 compounds Chemical class 0.000 description 8
241001465754 Metazoa Species 0.000 description 7
229940079593 drug Drugs 0.000 description 6
238000000034 method Methods 0.000 description 6
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
241000699670 Mus sp. Species 0.000 description 5
239000000935 antidepressant agent Substances 0.000 description 5
206010036067 polydipsia Diseases 0.000 description 5
206010034912 Phobia Diseases 0.000 description 4
230000001430 anti-depressive effect Effects 0.000 description 4
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
238000002474 experimental method Methods 0.000 description 4
208000008811 Agoraphobia Diseases 0.000 description 3
206010014405 Electrocution Diseases 0.000 description 3
VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 3
229920005372 Plexiglas® Polymers 0.000 description 3
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
239000002253 acid Substances 0.000 description 3
239000002671 adjuvant Substances 0.000 description 3
229940005513 antidepressants Drugs 0.000 description 3
230000000949 anxiolytic effect Effects 0.000 description 3
239000002775 capsule Substances 0.000 description 3
235000013305 food Nutrition 0.000 description 3
239000008187 granular material Substances 0.000 description 3
QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 3
239000011780 sodium chloride Substances 0.000 description 3
239000000243 solution Substances 0.000 description 3
201000001716 specific phobia Diseases 0.000 description 3
241000699666 Mus <mouse, genus> Species 0.000 description 2
MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 2
239000003085 diluting agent Substances 0.000 description 2
201000010099 disease Diseases 0.000 description 2
208000035475 disorder Diseases 0.000 description 2
239000006185 dispersion Substances 0.000 description 2
230000008030 elimination Effects 0.000 description 2
238000003379 elimination reaction Methods 0.000 description 2
238000002347 injection Methods 0.000 description 2
239000007924 injection Substances 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
230000003389 potentiating effect Effects 0.000 description 2
239000007787 solid Substances 0.000 description 2
208000024891 symptom Diseases 0.000 description 2
230000001960 triggered effect Effects 0.000 description 2
238000002604 ultrasonography Methods 0.000 description 2
208000007848 Alcoholism Diseases 0.000 description 1
206010003497 Asphyxia Diseases 0.000 description 1
206010008479 Chest Pain Diseases 0.000 description 1
206010008469 Chest discomfort Diseases 0.000 description 1
229920002261 Corn starch Polymers 0.000 description 1
206010012289 Dementia Diseases 0.000 description 1
208000020401 Depressive disease Diseases 0.000 description 1
208000000059 Dyspnea Diseases 0.000 description 1
206010013975 Dyspnoeas Diseases 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
206010028813 Nausea Diseases 0.000 description 1
206010033557 Palpitations Diseases 0.000 description 1
229920005439 Perspex® Polymers 0.000 description 1
230000002159 abnormal effect Effects 0.000 description 1
239000000654 additive Substances 0.000 description 1
201000007930 alcohol dependence Diseases 0.000 description 1
150000008064 anhydrides Chemical class 0.000 description 1
238000010171 animal model Methods 0.000 description 1
230000002426 anti-panic effect Effects 0.000 description 1
239000002249 anxiolytic agent Substances 0.000 description 1
230000004888 barrier function Effects 0.000 description 1
230000003542 behavioural effect Effects 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
230000037396 body weight Effects 0.000 description 1
208000026106 cerebrovascular disease Diseases 0.000 description 1
239000003086 colorant Substances 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
239000008120 corn starch Substances 0.000 description 1
238000011161 development Methods 0.000 description 1
235000005911 diet Nutrition 0.000 description 1
230000037213 diet Effects 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
238000009837 dry grinding Methods 0.000 description 1
238000004945 emulsification Methods 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
235000013355 food flavoring agent Nutrition 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
244000144993 groups of animals Species 0.000 description 1
-1 i.e. Chemical compound 0.000 description 1
239000012442 inert solvent Substances 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
208000011819 intense anxiety Diseases 0.000 description 1
238000002955 isolation Methods 0.000 description 1
239000008101 lactose Substances 0.000 description 1
230000002045 lasting effect Effects 0.000 description 1
230000006742 locomotor activity Effects 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
229910052751 metal Inorganic materials 0.000 description 1
239000002184 metal Substances 0.000 description 1
150000007522 mineralic acids Chemical class 0.000 description 1
238000002156 mixing Methods 0.000 description 1
239000000203 mixture Substances 0.000 description 1
230000008693 nausea Effects 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
235000015097 nutrients Nutrition 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
208000035824 paresthesia Diseases 0.000 description 1
239000002245 particle Substances 0.000 description 1
238000005192 partition Methods 0.000 description 1
208000022821 personality disease Diseases 0.000 description 1
239000000825 pharmaceutical preparation Substances 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
208000019899 phobic disease Diseases 0.000 description 1
239000004926 polymethyl methacrylate Substances 0.000 description 1
239000000843 powder Substances 0.000 description 1
238000001556 precipitation Methods 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
238000002203 pretreatment Methods 0.000 description 1
230000002265 prevention Effects 0.000 description 1
208000020016 psychiatric disease Diseases 0.000 description 1
238000001953 recrystallisation Methods 0.000 description 1
230000000306 recurrent effect Effects 0.000 description 1
239000011347 resin Substances 0.000 description 1
229920005989 resin Polymers 0.000 description 1
201000000980 schizophrenia Diseases 0.000 description 1
239000003762 serotonin receptor affecting agent Substances 0.000 description 1
230000000697 serotonin reuptake Effects 0.000 description 1
230000035939 shock Effects 0.000 description 1
208000013220 shortness of breath Diseases 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
239000000725 suspension Substances 0.000 description 1
230000035900 sweating Effects 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
239000003826 tablet Substances 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
235000012222 talc Nutrition 0.000 description 1
238000010998 test method Methods 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
238000005303 weighing Methods 0.000 description 1
238000001238 wet grinding Methods 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Epidemiology (AREA)
Psychiatry (AREA)
Pain & Pain Management (AREA)
Anesthesiology (AREA)
Oncology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Plural Heterocyclic Compounds (AREA)
Compounds Of Unknown Constitution (AREA)

BG11046709A 1999-07-08 2002-01-04 Treatment of neurotic disorders BG110467A (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
DKPA199900991		1999-07-08
PCT/DK2000/000377 WO2001003694A1 (fr)	1999-07-08	2000-07-07	Traitement de troubles nevrotiques

Publications (1)

Publication Number	Publication Date
BG110467A true BG110467A (en)	2010-01-29

Family

ID=8099796

Family Applications (4)

Application Number	Title	Priority Date	Filing Date
BG11046709A BG110467A (en)	1999-07-08	2002-01-04	Treatment of neurotic disorders
BG106279A BG106279A (bg)	1999-07-08	2002-01-04	Лечение на нервни разстройства
BG11046609A BG110466A (en)	1999-07-08	2002-01-04	Treatment of neurotic disorders
BG11046809A BG110468A (en)	1999-07-08	2002-01-04	Treatment of neurotic disorders

Family Applications After (3)

Application Number	Title	Priority Date	Filing Date
BG106279A BG106279A (bg)	1999-07-08	2002-01-04	Лечение на нервни разстройства
BG11046609A BG110466A (en)	1999-07-08	2002-01-04	Treatment of neurotic disorders
BG11046809A BG110468A (en)	1999-07-08	2002-01-04	Treatment of neurotic disorders

Country Status (38)

Country	Link
US (6)	US7271194B2 (fr)
EP (4)	EP1440690A3 (fr)
JP (1)	JP4773011B2 (fr)
KR (1)	KR100604176B1 (fr)
CN (1)	CN1198610C (fr)
AR (1)	AR021155A1 (fr)
AT (1)	ATE339955T1 (fr)
AU (6)	AU782514B2 (fr)
BG (4)	BG110467A (fr)
BR (1)	BR0011578A (fr)
CA (4)	CA2373757C (fr)
CL (3)	CL2008003941A1 (fr)
CO (1)	CO5190674A1 (fr)
CY (1)	CY1105806T1 (fr)
CZ (1)	CZ200270A3 (fr)
DE (1)	DE60030861T2 (fr)
DK (1)	DK1200081T3 (fr)
EA (1)	EA006555B1 (fr)
ES (1)	ES2272298T3 (fr)
HK (1)	HK1048069B (fr)
HR (1)	HRP20010820A2 (fr)
HU (1)	HUP0201791A3 (fr)
IL (5)	IL146131A0 (fr)
IS (1)	IS6137A (fr)
ME (2)	MEP2508A (fr)
MX (1)	MXPA01011626A (fr)
MY (1)	MY143278A (fr)
NO (4)	NO329021B1 (fr)
PL (1)	PL352030A1 (fr)
PT (1)	PT1200081E (fr)
SI (1)	SI1200081T1 (fr)
SK (1)	SK82002A3 (fr)
TR (4)	TR200402277T2 (fr)
TW (1)	TWI232101B (fr)
UA (1)	UA77645C2 (fr)
WO (1)	WO2001003694A1 (fr)
YU (1)	YU78701A (fr)
ZA (1)	ZA200108856B (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AR021155A1 (es) *	1999-07-08	2002-06-12	Lundbeck & Co As H	Tratamiento de desordenes neuroticos
GB0005477D0 (en)	2000-03-07	2000-04-26	Resolution Chemicals Limited	Process for the preparation of citalopram
CZ2003396A3 (cs) *	2000-07-21	2003-05-14	H. Lundbeck A/S	Inhibitory transportu glycinu
EA200301195A1 (ru) *	2001-05-01	2004-04-29	Х. Лундбекк А/С	Применение энантиомерно чистого эсциталопрама
HRP20031073A2 (en)	2001-07-31	2004-04-30	Lundbeck & Co As H	Crystalline composition containing escitalopram
AU2003237524A1 (en) *	2002-07-08	2004-01-23	University Of Florida	Use of ssri inhibitors to prevent or ameliorate trauma-related psychological disorders
CN100349885C (zh) *	2002-12-23	2007-11-21	H·隆德贝克有限公司	依他普仑氢溴酸盐及其制备方法
US20050137255A1 (en) *	2002-12-23	2005-06-23	H. Lundbeck A/S	Crystalline escitalopram hydrobromide and methods for preparing the same
TR200504022T1 (tr) *	2003-03-24	2006-08-21	Hetero Drugs Limited	(S)-sitalopram oksalatın yeni sıvı kristal formları.
US20090093461A1 (en) *	2003-07-02	2009-04-09	Astrazeneca Ab	Methods of Treating Anxiety and Mood Disorders
WO2005053796A1 (fr) *	2003-12-02	2005-06-16	B & B Beheer Nv	Utilisation d'antagonistes, d'agonistes inverses ou d'agonistes partiels d4 et 5ht2a,
US7884096B2 (en) *	2003-12-02	2011-02-08	Pharmaneuroboost N.V.	Method of treating mental disorders using of D4 and 5-HT2A antagonists, inverse agonists or partial agonists
US7855195B2 (en) *	2003-12-02	2010-12-21	Pharmaneuroboost N.V.	Method of treating mental disorders using D4 and 5-HT2A antagonists, inverse agonists or partial agonists
EP1954257A4 (fr)	2005-10-14	2009-05-20	Lundbeck & Co As H	Procedes de traitement de troubles du systeme nerveux central avec une combinaison de faible dose d'escitaloprame et de bupropion
US20070134322A1 (en) *	2005-12-14	2007-06-14	Forest Laboratories, Inc.	Modified and pulsatile release pharmaceutical formulations of escitalopram
FR2912057B1 (fr) *	2007-02-07	2009-04-17	Sanofi Aventis Sa	Composition pharmaceutique contenant en association le saredutant et un inhibiteur selectif de la recapture de la serotonine ou un inhibiteur de la recapture de la serotonine/norepinephrine
TW200817003A (en) *	2006-07-31	2008-04-16	Sanofi Aventis	Pharmaceutical composition comprising, in combination, saredutant and a selective serotonin peuptake inhibitor or a serotonin/norepinephrine reuptake inhibitor

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB1143703A (fr) *	1965-03-18
GB1526331A (en) *	1976-01-14	1978-09-27	Kefalas As	Phthalanes
US4436874A (en)	1981-11-19	1984-03-13	Societe D'expansion Scientifique "Expansia"	Acrylic copolymers and their use in solid phase peptide synthesis
GB8419963D0 (en) *	1984-08-06	1984-09-12	Lundbeck & Co As H	Intermediate compound and method
GB8607313D0 (en) *	1986-03-25	1986-04-30	Ici Plc	Pharmaceutical compositions
GB8814057D0 (en) *	1988-06-14	1988-07-20	Lundbeck & Co As H	New enantiomers & their isolation
US4902710A (en) *	1988-12-14	1990-02-20	Eli Lilly And Company	Serotonin and norepinephrine uptake inhibitors
US5114976A (en) *	1989-01-06	1992-05-19	Norden Michael J	Method for treating certain psychiatric disorders and certain psychiatric symptoms
US4962128A (en) *	1989-11-02	1990-10-09	Pfizer Inc.	Method of treating anxiety-related disorders using sertraline
US5296507A (en) *	1990-09-06	1994-03-22	H.Lundbeck A/S	Treatment of cerbrovascular disorders
DK213290D0 (da) *	1990-09-06	1990-09-06	Lundbeck & Co As H	Treatment of cerebrovascular disorders
US5708035A (en) *	1991-02-04	1998-01-13	Sepracor Inc.	Methods of use and compositions of R(-) fluoxetine
WO1992018005A1 (fr)	1991-04-16	1992-10-29	National Institutes Of Health	Procede de traitement de la trichotillomanie et de l'onychophagie
WO1993009769A1 (fr)	1991-11-15	1993-05-27	Sepracor, Inc.	Procedes et compositions a base de fluoxetine isomere s(+) pur
EP0714663A3 (fr)	1994-11-28	1997-01-15	Lilly Co Eli	Potentialisation d'un médicament par un antagoniste du récepteur sérotonine 1A
US5627196A (en) *	1995-01-17	1997-05-06	Eli Lilly And Company	Compounds having effects on serotonin-related systems
WO1996024353A1 (fr) *	1995-02-10	1996-08-15	Eli Lilly And Company	Procede de traitement ou de prevention de troubles psychiatriques
US5554383A (en) *	1995-04-06	1996-09-10	Trustees Of Tufts College	Veterinary method for clinically modifying the behavior of dogs exhibiting canine affective aggression
SE9501567D0 (sv) *	1995-04-27	1995-04-27	Astra Ab	A new combination
WO1997006792A1 (fr)	1995-08-16	1997-02-27	Eli Lilly And Company	Potentialisation de la production de serotonine
US5846982A (en) *	1996-06-14	1998-12-08	Eli Lilly And Company	Inhibition of serotonin reuptake
US5912256A (en) *	1996-06-20	1999-06-15	Eli Lilly And Company	Compounds having effects on serotonin-related systems
US5747494A (en) *	1996-06-28	1998-05-05	U C B S.A.	Pharmaceutical compositions for the treatment of depressive disorders
US5958429A (en) *	1996-08-16	1999-09-28	Eli Lilly And Company	Potentiation of serotonin response
ZA977967B (en) *	1996-09-23	1999-03-04	Lilly Co Eli	Combination therapy for treatment of psychoses
US5776969A (en) *	1997-02-27	1998-07-07	Eli Lilly And Company	Treatment of sleep disorders
US6069177A (en) *	1997-07-08	2000-05-30	The Hong Kong University Of Science And Technology	3-Hydroxy-propanamine derived neuronal reuptake inhibitors
SE9703379D0 (sv) *	1997-09-18	1997-09-18	Astra Ab	New compounds
SE9703375D0 (sv) *	1997-09-18	1997-09-18	Astra Ab	A new combination
ES2149734T3 (es) *	1997-11-11	2003-02-16	Lundbeck & Co As H	Metodo para la preparacion de citalopram.
EP0957099B1 (fr) *	1998-04-15	2002-11-20	Pfizer Products Inc.	Carboxamides hétérocycliques
JP2002519321A (ja) *	1998-06-30	2002-07-02	イーライ・リリー・アンド・カンパニー	セロトニン関連系に効果を有するピロリジン、及び、ピロリン誘導体
ATE355054T1 (de)	1998-07-13	2006-03-15	Nps Pharma Inc	Verfahren und verbindungen zur behandlung der depression
US6579899B1 (en)	1998-07-16	2003-06-17	Massachusetts Institute Of Technology	Composition for treatment of stress
EP1096927A4 (fr)	1998-07-16	2002-09-04	Massachusetts Inst Technology	Composition pour le traitement du stress
US6150376A (en) *	1998-08-05	2000-11-21	Georgetown University	Bi- and tri-cyclic aza compounds and their uses
SE9803158D0 (sv) *	1998-09-16	1998-09-16	Astra Ab	A new composition
SE9803157D0 (sv)	1998-09-16	1998-09-16	Astra Ab	A new composition
PL199423B1 (pl) *	1998-10-20	2008-09-30	Lundbeck & Co As H	Sposób wytwarzania citalopramu
AR021509A1 (es) *	1998-12-08	2002-07-24	Lundbeck & Co As H	Derivados de benzofurano, su preparacion y uso
NZ514671A (en) *	1999-04-14	2003-10-31	H	Method for the preparation of citalopram
AR021155A1 (es) *	1999-07-08	2002-06-12	Lundbeck & Co As H	Tratamiento de desordenes neuroticos
US6333357B1 (en) *	1999-11-05	2001-12-25	Be Able, Llc	Behavior chemotherapy
UA77650C2 (en) *	1999-12-06	2007-01-15	Lundbeck & Co As H	Use of serotonin reuptake inhibitor in combination with deramcyclane
GB2357762B (en) *	2000-03-13	2002-01-30	Lundbeck & Co As H	Crystalline base of citalopram
EP1276478A2 (fr) *	2000-04-24	2003-01-22	ARYx Therapeutics	Substances et methodes de traitement de la depression
JP2002361405A (ja) *	2000-09-25	2002-12-18	Showa Denko Kk	熱交換器の製造方法
EA200301195A1 (ru) *	2001-05-01	2004-04-29	Х. Лундбекк А/С	Применение энантиомерно чистого эсциталопрама

2000
- 2000-07-06 AR ARP000103442A patent/AR021155A1/es unknown
- 2000-07-07 EP EP04007521A patent/EP1440690A3/fr not_active Withdrawn
- 2000-07-07 BR BR0011578-9A patent/BR0011578A/pt active Search and Examination
- 2000-07-07 SK SK8-2002A patent/SK82002A3/sk not_active Application Discontinuation
- 2000-07-07 CO CO00051031A patent/CO5190674A1/es not_active Application Discontinuation
- 2000-07-07 ME MEP-25/08A patent/MEP2508A/xx unknown
- 2000-07-07 JP JP2001508974A patent/JP4773011B2/ja not_active Expired - Lifetime
- 2000-07-07 SI SI200030910T patent/SI1200081T1/sl unknown
- 2000-07-07 HU HU0201791A patent/HUP0201791A3/hu unknown
- 2000-07-07 AT AT00943692T patent/ATE339955T1/de active
- 2000-07-07 DE DE60030861T patent/DE60030861T2/de not_active Expired - Lifetime
- 2000-07-07 CA CA002373757A patent/CA2373757C/fr not_active Expired - Lifetime
- 2000-07-07 TR TR2004/02277T patent/TR200402277T2/xx unknown
- 2000-07-07 EA EA200200137A patent/EA006555B1/ru not_active IP Right Cessation
- 2000-07-07 EP EP04007520A patent/EP1440689A3/fr not_active Withdrawn
- 2000-07-07 PL PL00352030A patent/PL352030A1/xx not_active Application Discontinuation
- 2000-07-07 CN CNB008100292A patent/CN1198610C/zh not_active Expired - Lifetime
- 2000-07-07 YU YU78701A patent/YU78701A/sh unknown
- 2000-07-07 CA CA2687394A patent/CA2687394A1/fr not_active Abandoned
- 2000-07-07 HR HR20010820A patent/HRP20010820A2/hr not_active Application Discontinuation
- 2000-07-07 EP EP04007522A patent/EP1440691A3/fr not_active Withdrawn
- 2000-07-07 CA CA2687396A patent/CA2687396A1/fr not_active Abandoned
- 2000-07-07 IL IL14613100A patent/IL146131A0/xx unknown
- 2000-07-07 AU AU58061/00A patent/AU782514B2/en not_active Expired
- 2000-07-07 TR TR2002/00014T patent/TR200200014T2/xx unknown
- 2000-07-07 EP EP00943692A patent/EP1200081B1/fr not_active Revoked
- 2000-07-07 CZ CZ200270A patent/CZ200270A3/cs unknown
- 2000-07-07 ES ES00943692T patent/ES2272298T3/es not_active Expired - Lifetime
- 2000-07-07 WO PCT/DK2000/000377 patent/WO2001003694A1/fr not_active Ceased
- 2000-07-07 MY MYPI20003122A patent/MY143278A/en unknown
- 2000-07-07 ME MEP-2008-25A patent/ME00032B/fr unknown
- 2000-07-07 CA CA2687392A patent/CA2687392A1/fr not_active Abandoned
- 2000-07-07 KR KR1020017016006A patent/KR100604176B1/ko not_active Ceased
- 2000-07-07 TR TR2004/02276T patent/TR200402276T2/xx unknown
- 2000-07-07 PT PT00943692T patent/PT1200081E/pt unknown
- 2000-07-07 HK HK03100231.6A patent/HK1048069B/zh not_active IP Right Cessation
- 2000-07-07 UA UA2001128286A patent/UA77645C2/uk unknown
- 2000-07-07 MX MXPA01011626A patent/MXPA01011626A/es not_active Application Discontinuation
- 2000-07-07 DK DK00943692T patent/DK1200081T3/da active
- 2000-07-07 TR TR2004/02275T patent/TR200402275T2/xx unknown
- 2000-07-28 TW TW089115110A patent/TWI232101B/zh not_active IP Right Cessation
2001
- 2001-10-23 IL IL146131A patent/IL146131A/en active IP Right Grant
- 2001-10-26 ZA ZA200108856A patent/ZA200108856B/xx unknown
- 2001-10-30 IS IS6137A patent/IS6137A/is unknown
- 2001-12-12 US US10/021,126 patent/US7271194B2/en not_active Expired - Lifetime
2002
- 2002-01-04 BG BG11046709A patent/BG110467A/bg unknown
- 2002-01-04 BG BG106279A patent/BG106279A/bg unknown
- 2002-01-04 BG BG11046609A patent/BG110466A/bg unknown
- 2002-01-04 BG BG11046809A patent/BG110468A/bg unknown
- 2002-01-07 NO NO20020062A patent/NO329021B1/no not_active IP Right Cessation
2003
- 2003-08-07 US US10/637,822 patent/US20040029958A1/en not_active Abandoned
- 2003-08-07 US US10/637,820 patent/US7265151B2/en not_active Expired - Lifetime
- 2003-08-07 US US10/637,821 patent/US20040029957A1/en not_active Abandoned
- 2003-08-20 US US10/644,143 patent/US6960613B2/en not_active Expired - Lifetime
2005
- 2005-06-20 AU AU2005202685A patent/AU2005202685B2/en not_active Ceased
- 2005-06-20 AU AU2005202686A patent/AU2005202686B2/en not_active Expired
- 2005-06-20 AU AU2005202684A patent/AU2005202684B2/en not_active Ceased
- 2005-08-09 IL IL170192A patent/IL170192A/en unknown
- 2005-08-09 IL IL170194A patent/IL170194A/en unknown
- 2005-08-09 IL IL170193A patent/IL170193A/en unknown
2006
- 2006-11-27 CY CY20061101706T patent/CY1105806T1/el unknown
2007
- 2007-08-10 US US11/837,317 patent/US20070276035A1/en not_active Abandoned
2008
- 2008-12-24 AU AU2008264188A patent/AU2008264188A1/en not_active Withdrawn
- 2008-12-24 AU AU2008264182A patent/AU2008264182A1/en not_active Withdrawn
- 2008-12-30 CL CL2008003941A patent/CL2008003941A1/es unknown
- 2008-12-30 CL CL2008003938A patent/CL2008003938A1/es unknown
- 2008-12-30 CL CL2008003939A patent/CL2008003939A1/es unknown
2010
- 2010-03-10 NO NO20100334A patent/NO20100334L/no not_active Application Discontinuation
- 2010-03-10 NO NO20100333A patent/NO20100333L/no not_active Application Discontinuation
- 2010-03-10 NO NO20100335A patent/NO20100335L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
TR200402276T2 (tr)	2005-01-24
AU2008264182A1 (en)	2009-01-29
IL146131A (en)	2007-02-11
EP1440689A2 (fr)	2004-07-28
DK1200081T3 (da)	2006-12-27
JP4773011B2 (ja)	2011-09-14
DE60030861T2 (de)	2007-05-03
HRP20010820A2 (en)	2003-08-31
CO5190674A1 (es)	2002-08-29
KR100604176B1 (ko)	2006-07-25
EP1440690A3 (fr)	2004-08-18
AU5806100A (en)	2001-01-30
HK1048069A1 (en)	2003-03-21
NO20100334L (no)	2002-01-07
WO2001003694A1 (fr)	2001-01-18
US20020086899A1 (en)	2002-07-04
BG106279A (bg)	2002-08-30
IL170192A (en)	2010-04-29
MEP2508A (xx)	2010-02-10
NO329021B1 (no)	2010-07-26
BR0011578A (pt)	2002-03-26
BG110468A (en)	2010-01-29
PL352030A1 (en)	2003-07-28
ME00032B (fr)	2010-02-10
TR200200014T2 (tr)	2002-05-21
BG110466A (en)	2010-01-29
HUP0201791A3 (en)	2005-02-28
AU2005202685A1 (en)	2005-07-14
CL2008003938A1 (es)	2009-05-22
EP1200081A1 (fr)	2002-05-02
AU2005202684A1 (en)	2005-07-14
HUP0201791A2 (en)	2002-10-28
CA2687396A1 (fr)	2001-01-18
ATE339955T1 (de)	2006-10-15
NO20100333L (no)	2002-01-07
AR021155A1 (es)	2002-06-12
IS6137A (is)	2001-10-30
CL2008003941A1 (es)	2009-05-22
MXPA01011626A (es)	2002-06-04
AU782514B2 (en)	2005-08-04
US20040029958A1 (en)	2004-02-12
CZ200270A3 (cs)	2002-04-17
NO20020062D0 (no)	2002-01-07
US7271194B2 (en)	2007-09-18
CA2687392A1 (fr)	2001-01-18
YU78701A (sh)	2004-03-12
EP1440690A2 (fr)	2004-07-28
EA006555B1 (ru)	2006-02-24
US6960613B2 (en)	2005-11-01
EP1440691A3 (fr)	2004-08-25
US20040029956A1 (en)	2004-02-12
CA2373757C (fr)	2010-01-05
US20040029957A1 (en)	2004-02-12
AU2005202686B2 (en)	2009-01-15
IL170194A (en)	2010-05-31
CN1198610C (zh)	2005-04-27
US7265151B2 (en)	2007-09-04
EP1200081B1 (fr)	2006-09-20
AU2005202684B2 (en)	2009-01-15
ZA200108856B (en)	2002-12-24
AU2008264188A1 (en)	2009-05-07
IL146131A0 (en)	2002-07-25
TR200402277T2 (tr)	2005-01-24
JP2003504332A (ja)	2003-02-04
SK82002A3 (en)	2002-07-02
MY143278A (en)	2011-04-15
HK1048069B (zh)	2005-12-16
EP1440689A3 (fr)	2004-08-25
US20070276035A1 (en)	2007-11-29
CY1105806T1 (el)	2011-02-02
KR20020015346A (ko)	2002-02-27
CA2373757A1 (fr)	2001-01-18
NO20020062L (no)	2002-01-07
SI1200081T1 (sl)	2007-02-28
CN1360501A (zh)	2002-07-24
CA2687394A1 (fr)	2001-01-18
DE60030861D1 (de)	2006-11-02
TR200402275T2 (tr)	2005-03-21
IL170193A (en)	2010-04-29
ES2272298T3 (es)	2007-05-01
AU2005202686A1 (en)	2005-07-14
EA200200137A1 (ru)	2002-06-27
UA77645C2 (en)	2007-01-15
NO20100335L (no)	2002-01-07
AU2005202685B2 (en)	2009-01-15
CL2008003939A1 (es)	2009-06-05
US20050101665A1 (en)	2005-05-12
TWI232101B (en)	2005-05-11
EP1440691A2 (fr)	2004-07-28
PT1200081E (pt)	2007-01-31